This study investigated the effects of liraglutide, a GLP-1 receptor agonist used in diabetes treatment, on Alzheimer's disease (AD) pathology using APP/PS1 transgenic mice. Liraglutide was administered peripherally at a dose of 25 nmol/kg body weight daily for 8 weeks to 7-month-old APP/PS1 mice and wild-type controls. The study assessed
